John Tedesco, Thoracic Surgeon at Norton Thoracic Institute shared a post on LinkedIn:
“Neoadjuvant chemo-immunotherapy is no longer just an oncology story-it’s a surgical one. As trials continue to show deep pathologic responses and improved survival in resectable NSCLC, the question for surgeons is shifting from “Can I resect this?” to “Does surgery still add value here and when?”
Traditional anatomic definitions of resectability are being challenged by immune-mediated downstaging, ctDNA clearance, and biologic response that imaging doesn’t always capture.
For surgeons, this means earlier involvement, tighter collaboration with medical oncology, and a bigger role in defining who truly benefits from an operation versus alternative curative pathways. The OR is no longer the finish line: it’s one decision point in a biologically driven continuum of care.
Curious to see how this reshapes MDT discussions and surgical candidacy over the next few years.”
Title: Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies
Authors: Akshay Patel, Elliot Wakeam, Eleni Josephides, Savvas Lampridis, Eleni Karapanagiotou, Gary Middleton, Babu Naidu, Marc De Perrot, Andrea Bille
Read The Full Article
Other articles about Chemoimmunotherapy on OncoDaily.